MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530201 | Name: Tabimorelin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tabimorelin is a growth hormone releasing factor agonist potentially for the treatment of growth hormone deficit. Tabimorelin is a drug which acts as a potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue, mimicking the effects of the endogenous peptide agonist ghrelin as a stimulator of growth hormone (GH) release.

Chemical Structure

Tabimorelin
Tabimorelin
CAS#193079-69-5

Theoretical Analysis

MedKoo Cat#: 530201

Name: Tabimorelin

CAS#: 193079-69-5

Chemical Formula: C32H40N4O3

Exact Mass: 528.3100

Molecular Weight: 528.70

Elemental Analysis: C, 72.70; H, 7.63; N, 10.60; O, 9.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Tabimorelin, NN-703, NNC-26-0703, NNC-260703, NN703, NNC26-0703, NNC260703
IUPAC/Chemical Name
(E)-5-amino-N,5-dimethyl-N-((R)-1-(methyl((R)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)hex-2-enamide
InChi Key
WURGZWOTGMLDJP-ZCYANPAGSA-N
InChi Code
InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
SMILES Code
CC(C)(N)C/C=C/C(N(C)[C@@H](C(N(C)[C@@H](C(NC)=O)CC1=CC=CC=C1)=O)CC2=CC=C3C=CC=CC3=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 528.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lange T, Thomas A, Görgens C, Bidlingmaier M, Schilbach K, Fichant E, Delahaut P, Thevis M. Comprehensive insights into the formation of metabolites of the ghrelin mimetics capromorelin, macimorelin and tabimorelin as potential markers for doping control purposes. Biomed Chromatogr. 2021 Jun;35(6):e5075. doi: 10.1002/bmc.5075. Epub 2021 Feb 2. PMID: 33458843. 2: Shimatsu A. [Ghrelin-related drugs: clinical perspectives]. Nihon Rinsho. 2004 Sep;62 Suppl 9:435-8. Japanese. PMID: 15506422. 3: Holm AM, Johansen PB, Ahnfelt-Rønne I, Rømer J. Adipogenic and orexigenic effects of the ghrelin-receptor ligand tabimorelin are diminished in leptin- signalling-deficient ZDF rats. Eur J Endocrinol. 2004 Jun;150(6):893-904. doi: 10.1530/eje.0.1500893. PMID: 15191361. 4: Svensson J, Monson JP, Vetter T, Hansen TK, Savine R, Kann P, Bex M, Reincke M, Hagen C, Beckers A, Ilondo MM, Zdravkovic M, Bengtsson BA, Korbonits M; NN703 Clinical Research Group. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf). 2003 May;58(5):572-80. doi: 10.1046/j.1365-2265.2003.01754.x. PMID: 12699438. 5: Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, Rasmussen MH, Ilondo MM. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Eur J Clin Pharmacol. 2003 Feb;58(10):683-8. doi: 10.1007/s00228-002-0539-1. Epub 2003 Feb 6. PMID: 12610745. 6: Nielsen KK, Buddington KK, Raun K, Hansen TK, Buddington RK. Absorption and systemic availability of two synthetic growth hormone secretogogues and transport of glucose by the proximal small intestine of anestrus dogs after administering estradiol. J Comp Physiol B. 2003 Feb;173(1):61-7. doi: 10.1007/s00360-002-0312-x. Epub 2003 Jan 9. PMID: 12592444. 7: Peschke B, Ankersen M, Bauer M, Hansen TK, Hansen BS, Nielsen KK, Raun K, Richter L, Westergaard L. The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. Eur J Med Chem. 2002 Jun;37(6):487-501. doi: 10.1016/s0223-5234(02)01370-3. PMID: 12204475. 8: Malmlöf K, Bauer MK, Johansen PB, Ankersen M, Veldhuis JD. Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs. Endocrine. 2001 Dec;16(3):195-9. doi: 10.1385/ENDO:16:3:195. PMID: 11954663. 9: Hansen TK, Ankersen M, Raun K, Hansen BS. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1915-8. doi: 10.1016/s0960-894x(01)00345-6. PMID: 11459660. 10: Zdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch JF, Søgaard B, Ynddal L, Ilondo MM. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. Growth Horm IGF Res. 2001 Feb;11(1):41-8. doi: 10.1054/ghir.2000.0188. PMID: 11437473. 11: Ahnfelt-Rønne I, Nowak J, Olsen UB. Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine. 2001 Feb;14(1):133-5. doi: 10.1385/ENDO:14:1:133. PMID: 11322495. 12: Agersø H, Ynddal L, Søgaard B, Zdravkovic M. Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers. J Clin Pharmacol. 2001 Feb;41(2):163-9. doi: 10.1177/00912700122009971. PMID: 11210396. 13: Zdravkovic M, Christiansen T, Grosch K, Ilondo MM. Evaluation of the conformity of human growth hormone concentrations measured with the DPC Immulite and the Nichols Advantage assays. Clin Chem Lab Med. 2000 Aug;38(8):799-800. doi: 10.1515/CCLM.2000.114. PMID: 11071076. 14: Zdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen MS, Falch JE, Ilondo MM. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Horm IGF Res. 2000 Aug;10(4):193-8. doi: 10.1054/ghir.2000.0152. PMID: 11032702. 15: Peschke B, Ankersen M, Hansen TK, Hansen BS, Lau J, Nielsen KK, Raun K. New highly potent dipeptidic growth hormone secretagogues with low molecular weight. Eur J Med Chem. 2000 Jun;35(6):599-618. doi: 10.1016/s0223-5234(00)00160-4. PMID: 10906412. 16: Ankersen M, Kramer Nielsen K, Kruse Hansen T, Raun K, Sehested Hansen B. Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal. Eur J Med Chem. 2000 May;35(5):487-97. doi: 10.1016/s0223-5234(00)00146-x. PMID: 10889328. 17: Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9. doi: 10.1530/eje.0.1410180. PMID: 10427162. 18: Peschke B, Hansen BS. New growth hormone secretagogues: C-terminal modified sulfonamide-analogues of NN703. Bioorg Med Chem Lett. 1999 May 3;9(9):1295-8. doi: 10.1016/s0960-894x(99)00167-5. PMID: 10340617.

View History

LY3295668

LY3295668

Featured